Phosphodiesterase 5 (PDE5) inhibitors are efficacious in treating patients with erectile dysfunction. New PDE5 inhibitors with different selectivity and pharmacokinetic profiles have been vigorously pursued. Here we report two novel, potent, and selective PDE5 inhibitors, JNJ-10280205 and JNJ-10287069, with K i values of 0.05 and 0.12 nM, respectively. Both compounds displayed superior selectivity against PDE1-4 and -6 when compared to sildenafil. In the anesthetized dogs, JNJ-10280205 and JNJ-10287069 exhibited similar efficacy as sildenafil in enhancing erectile functions, with no significant effect on cardiovascular parameters. Pharmacokinetic studies showed that JNJ-10287069 had better oral bioavailability than JNJ-10280205 in several animal species. In vitro study suggested that cytochrome P450 (CYP) 3A4 played a major role in the metabolism of both compounds. The compounds inhibited some of the CYP450 enzymes and the human ether-a-go-go (HERG) channel at much higher concentrations than that required to inhibit PDE5, thus, no cross inhibition would be expected at therapeutic doses. Both compounds are suitable clinical candidates.
Introduction
Penile erection is a vascular event.
1 Upon stimulation, cavernosal smooth muscle and the associated arterioles relax and the blood flow into the sinusoids increases. This results in distention of the cavernosal bodies and blockade of venous outflow, leading to a rigid erection. It is well established that the relaxation process leading to erection is mediated primarily through the nitric oxide (NO)/cGMP pathway. [2] [3] [4] During the initiation phase of erection, NO is released from non-cholinergic, non-adrenergic neurons and the endothelial cells. It activates soluble guanylyl cyclase in the cavernosal smooth muscle cells and arterioles, induces cGMP accumulation in these cells, and eventually leads to a decrease of intracellular calcium levels and smooth muscle cell relaxation. Thus, the ability to reach sufficiently high concentrations of intracellular cGMP is critical for achieving a successful erection. PDE5 is the major phosphodiesterase that degrades cGMP in human penile tissue. In patients with organic erectile dysfunction, the intracellular cGMP concentrations are often not sufficient to induce adequate smooth muscle relaxation. Inhibition of phosphodiesterase 5 (PDE5) activity facilitates cGMP accumulation upon sexual stimulation and hence enhances the erection. 5, 6 Phosphodiesterase 5 belongs to the PDE superfamily. To date, 21 mammalian PDE genes have been cloned and classified into 11 families according to the sequence homology and biochemical properties. 7 It is common that a PDE gene has multiple spicing variants. The differential expressions of various PDE genes and their variants in different tissues and cell types provide the opportunities for the development of specific PDE inhibitors in a wide range of therapeutic areas. 8 The clinical performance of the first oral PDE5 inhibitor, sildenafil, provided unequivocal proof that it is very efficacious in treating patients with mild to moderate erectile dysfunction. [9] [10] [11] Since the successful launch of sildenafil, vardenafil and tadalafil have also entered the market 12 and several other potent and selective PDE5 inhibitors have been reported in the literature. 13 We have previously reported a novel series of PDE5 inhibitors.
14 Here, we characterize two leading compounds from that series, JNJ-10280205 and JNJ-10287069. [3,4-b] quinolin-9-one) and JNJ-10287069 (R-3-(2,3-dihydro-benzofuran-5-yl)-2-pyridin-2-yl-1, 2,3,4-tetrahydro-pyrrolo [3,4-b] quinolin-9-one were synthesized as previously described and methane sulfonate salts were used. 14 Phosphodiesterase assays Phosphodiesterase 1-6 assays were partially purified from various human tissues as described previously. 15 Human recombinant PDE11A4 was generated as described. 16 Phosphodiesterase assays were carried out as previously described. 15 The amount of enzyme used in each reaction was such that the hydrolysis of substrates did not exceed 15% of the total, ensuring that the amount of product increased linearly with respect to time. Percent inhibition was used to generate IC 50 values by fitting the data to a nonlinear regression model in GraphPad Prism. At very low concentrations of substrate ([S]5K m ), these IC 50 values approximate the K i values.
Materials and methods

Materials
JNJ-10280205 (R-3-(2,3-dihydro-5-benzofuranyl)- 1,2,3,4-tetrahydro-2-[5-(2-pyridinyl)-2-pyrimidinyl- 9H-pyrrolo
Anesthetized dog model
All animals were handled in accordance with the NRC Guide for Care and Use of Laboratory Animals, and the protocol was approved by the Internal Animal Care and Usage Committee of Johnson & Johnson Pharmaceutical Research & Development, LLC. The animals were prepared and efficacy study was carried out as described previously. 15 Compounds were dissolved in 10% solutol prepared in 5% dextrose. Ascending doses of compound were administrated via bolus injection to the right femoral vein at 40 min intervals. The effect of compound on the increase in intracavernosal pressure was evaluated 15 min after each dose by electrical stimulation with the frequency setting the baseline. At the end of each experiment, 300 mg/ kg sildenafil was given the same way as the testing compound. This dose was shown to induce a maximal response in our hands. For each animal, the highest response was designated as 100%. Heart rate and mean aortic blood pressure were monitored throughout the experiment. Immediately after each efficacy evaluation, blood samples were taken with heparinized Vacutainer s tubes (BD, Franklin Lakes, NJ, USA) from the femoral vein. The plasma was separated by centrifugation and compound concentrations were determined using an LC-MS/MS assay procedure.
Single dose pharmacokinetic study Male Sprague-Dawley rats, male Beagle dogs, and male Cynomolgus monkeys in good general health were randomly chosen for the studies. All animals were fasted overnight before dosing. Each animal received a single oral or intravenous bolus dose of a compound in an appropriate formulation. In total, 10% solutol in 5% Dextrose, and 20 or 40% hydroxypropyl-beta-cyclodextrin (HPBCD) were used for intravenous (i.v.) dosing formulation; 0.5% methylcellulose (Methocel s ) was used for all oral (p.o.) dosing formulations. Blood samples were collected from the retro-orbital sinus in rats, and the jugular or cephalic vein in dogs and primates into heparinized Vacutainer s tubes at predose, 0.25, 0.5, 1, 2, 4, 8, and 24 h postdose following oral dosing and at predose, 0.08, 0.25, 0.50, 1, 2, 4, 8, and 24 h postdose following i.v. dosing. All samples were kept on ice until the plasma was separated by centrifugation, and then the plasma was stored frozen at À801C.
To quantify the amount of compound in plasma, 200 ml acetonitrile containing internal standard was added to 100 ml of plasma to precipitate proteins. The samples were centrifuged at 3000 g for 5 min and the supernatant was removed for analysis by LC-MS/MS. Calibration standards and quality control samples were prepared by adding appropriate volumes of stock solution directly into plasma and treated identically to the collected plasma samples. Calibration standards were prepared in the range of 0.01-10 mg/ml for quantitation. All plasma samples were analyzed with an LC-MS/MS assay procedure using selected ion monitoring for detection of characteristic ions for each candidate, and the internal standard used was propranolol for positive ions or chloramphenicol for negative ions. Pharmacokinetic analysis of the plasma concentration data was performed to generate various parameters, using the WinNonlin (Version 1.5, Pharsight, Palo Alto, CA, USA) program with non-compartmental model. The percent bioavailability (F) of the oral dose was calculated by comparing the individual oral AUC values for each animal to the mean i.v. AUC value.
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Cytochrome P450 enzyme profiling study and enzyme inhibition study Microsomes containing individual human recombinant cytochrome P450 (CYP) enzymes (CYP1A2, 2C9, 2C19, 2D6, and 3A4) were obtained from Gentest Corp. (Woburn, MA, USA) and used in both the studies. For the profiling study, compounds were diluted to 4 mM in phosphate buffer (pH 7.4) containing glucose-6-phosphate, NADP þ, and glucose-6-phosphate dehydrogenase. The enzymatic reaction was initiated by adding an equal volume of individual P450 enzyme and was stopped by adding acetonitrile to the reaction mixture at the desired time points. An LC-MS/MS method was used to measure the test compound remaining in the reaction mixtures after incubation. The results were expressed as percentages relative to no incubation (T ¼ 0 min). The enzyme inhibition study was carried out as described with minor modification.
17
The compounds were serially diluted in phosphate buffer (pH 7.4) containing the electron generating system. The enzymatic reaction was initiated by adding individual CYP450 enzymes pre-mixed with specific fluorescent substrates, and stopped by adding acetonitrile to the reaction mixture after 20-min incubation at 371C. The fluorescence of metabolites was measured. The results were expressed as percent inhibition relative to the control (no testing compound). The substrates used for the assays were dibenzylfluorescein for CYP2C9 and CYP2C19, 3-cyano-7-ethoxycoumarin for CYP1A2, 3-[2-(N,Ndiethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin for CYP2D6, and 7-benzyloxy-4-trifloromethylcoumarin for CYP3A4.
HERG channel study
Human ether-a-go-go (HERG) channel study was carried out in stably transfected HEK293 (human embryonic kidney) cells. 18 The cells were held at À75 mV and depolarized to þ 20 mV for 2 s, followed by a 1 s pulse to À40 mV to measure the tail current. This paradigm was delivered once every 5 s to monitor the current amplitude. Once the current amplitude was stable, testing compound was delivered to the extracellular side of the cell by bath perfusion. During perfusion, the cell was repetitively stimulated with the protocol described above and the current amplitude was monitored continuously. The degree of drug inhibition was obtained by measuring the tail current amplitude before and after perfusion. Dose-response curves for compounds were generated with five sequentially perfused concentrations. Two cells were tested for each compound. IC 50 values were determined by fitting the data to a nonlinear regression model in GraphPad Prism. The reference compounds were tested in separate studies and expected results were obtained.
Results
The inhibitory effects of JNJ-10280205 and JNJ-10287069 were tested on partially purified human PDE1-6 and recombinant PDE11A4 (Table 1) . Sildenafil was used as the comparator in each assay. Both JNJ compounds were very potent against human PDE5. With K i values of 0.05 and 0.12 nM, JNJ-10280205 and JNJ-10287069 were 37 and 16 times more potent than sildenafil, respectively. They exhibited better selectivity than sildenafil on most of the other phosphodiesterases tested, especially on PDE1 and 6. JNJ-10287069 had better selectivity against PDE6 and PDE11A4 than JNJ-10280205.
To assess the in vivo efficacies of the two compounds, their abilities to enhance the amplitude and duration of the intracavernosal pressure (ICP) increase initiated by electrical stimulation to the pelvic nerve of anesthetized dogs were determined. All compounds were administrated intravenously in an ascending dosage manner and produced (Figure 1 ). The heart rate and mean aortic blood pressure were monitored continuously during the course of the experiments. Neither JNJ-10287069, JNJ-10280205, nor sildenafil induced statistically significant changes in heart rate or mean blood pressure at any of the doses tested as determined by one-way analysis of variants (P40.05, data not shown).
As the pharmacokinetic properties are important determinants on whether a compound could be developed into an oral therapeutic, the pharmacokinetic parameters of both JNJ compounds in rat, dog, and monkey were determined. In 0.5% methylcellulose, JNJ-10287069 showed better bioavailability than JNJ-10280205 in male rats, dogs, and monkeys (Table 2, Figure 2) .
Several ancillary pharmacological studies were carried out after the efficacy was demonstrated. Recombinant human CYP1A2, 2D6, 2C9, 2C19, and 3A4 were used to determine the major enzyme responsible for JNJ-10280205 and JNJ-10287069 metabolism. CYP3A4 was largely responsible for the metabolism of JNJ-10280205 in vitro and CYP1A2 contributed moderately, whereas CYP2C9, 2C19, and 2D6 had little contribution (Figure 3 ). For JNJ-10287069, CYP3A4 played a major role, CYP2D6 was moderately involved, and CYP1A2 played a minor role in JNJ-10287069 in vitro degradation (data not shown). The ability of the JNJ compounds to inhibit human CYP enzymes was also determined (Table 3) . Similar results were obtained for JNJ-10287069 and JNJ-10280205. Both compounds inhibited CYP enzymes at much higher concentrations than those inhibiting PDE5. The ability of the compounds to inhibit HERG tail currents was also investigated. JNJ-10280205 inhibited HERG with an IC 50 of 7.48 mM, whereas JNJ-10287069 had an IC 50 of 3.33 mM (Figure 4 ).
Discussion
Ever since sildenafil was shown to be an effective first-line therapy for erectile dysfunction, tremendous effort has been devoted to search for new and better PDE5 inhibitors. Numerous PDE5 inhibitors have been reported in the past couple of years, 13 including vardenafil and tadalafil, both of which are 13 Sildenafil, vardenafil, tadalafil, and the two JNJ compounds all show excellent selectivity against PDE2, 3, and 4. 9, 19, 20 The point of differentiation would be on PDE1 and 6, against which sildenafil presents 180-and 11-fold selectivity, respectively. 9 Vardenafil has an IC 50 value of 0.7 nM against PDE5 and 251-and 16-fold greater selectivity against PDE1 and PDE6, respectively. 19 Tadalafil, with an IC 50 value of 5 nM, exhibits much improved selectivity against PDE1 (42000-fold) and PDE6 (1000-fold). 20 Similar to tadalafil, the two JNJ compounds display much better selectivity against these two PDEs. Cross inhibition of PDE6 by sildenafil is responsible for its visual disturbance side effects observed clinically. Vardenafil shows similar to slightly better selectivity against PDE6 than sildenafil. 19, 21 With this selectivity and better trial design, no visual side effects has been reported in vardenafil clinical trials. 21, 22 JNJ-10280205 has a selectivity against PDE6 that is 8-16-fold better than that of sildenafil, whereas JNJ-10287069 exhibits 15-26-fold better selectivity against PDE6 than sildenafil. Therefore, no visual side effect is expected clinically.
The only enzyme on which the JNJ compounds displayed inferior selectivity compared to sildenafil was PDE11A4. PDE11A is the most recently cloned PDE. [23] [24] [25] It has four splicing variants (11A1-4) and hydrolyzes both cAMP and cGMP. PDE11A4 is the largest of the four variants and its N-terminus contains multiple domains normally associated with regulatory processes. The tissue distribution of PDE11A isoforms is controversial, but its presence in testis and prostate is widely % Inhibition of tail current Figure 4 Effect of JNJ-10280205 and JNJ-10287069 on HERG tail current. Tail current before compound perfusion was designated as 100%. Ascending concentrations of a compound were perfused and tail currents were measured and compared to baseline. N ¼ 2.
JNJ-10280205 and JNJ-10287069 Y Qiu et al accepted. 16, 23, 25 The physiological function of PDE11A is poorly understood. It was reported that tadalafil had 5.5-and 40-fold selectivity against PDE11A1 26 and PDE11A4, 27 respectively. Studies in dogs showed that when administrated daily for 6 and 12 months, there were changes in seminiferous epithelium that resulted in a decrease in spermatogenesis in some dogs. However, a recent clinical study demonstrated that when taken by healthy men or men with mild ED at 10 or 20 mg daily dose for 6 months, tadalafil had no adverse effect on spermatogenesis. 18 As both JNJ compounds have better selectivity than tadalafil against PDE11A, neither compound would be expected to have any adverse effect on human spermatogenesis.
JNJ-10280205 and JNJ-10287069 were as efficacious as sildenafil in an anesthetized dog erectile model. However, both JNJ compounds were slightly less potent than sildenafil. This was not predicted as both compounds had improved potencies over sildenafil in the enzyme assay and a cell-based assay. 11 This discrepancy may be explained by their differences in plasma protein binding in dogs. Both JNJ-10287069 and JNJ-10280205 were extensively protein-bound with mean plasma protein binding of 97.82 and 99.0% in dog plasma (unpublished data), respectively, whereas sildenafil was 86% bound. 28 The concentration of the compound in the plasma that was reported was the total compound concentration, including both the free and bound compound. Thus, at similar doses, the free sildenafil concentrations would be predicted to be higher than the concentrations of the free JNJ compounds in the dog plasma. As only the free compound could access the target enzyme, the result of the in vivo study is consistent with the in vitro study in terms of the rank order of potency.
For a compound to become a therapeutic agent, having desired biochemical and pharmacological properties only fulfill part of the requirement. Another very important criterion for the compound is the pharmacokinetic properties. Although pharmacokinetic properties of a compound in animals does not always predict what a human body would do to the compound, studies in animals give us much useful information. JNJ-10280205 showed poor bioavailability in 0.5% methylcellulose in all three animal species tested. JNJ-10287069 was later developed to rectify this deficit. It achieved oral bioavailability of 56, 69, and 40% in male rats, dogs, and monkeys, respectively, compared with 11, 20, and o1% for JNJ-10280205. Whereas the t max for the two compounds is very similar in all three species, the C max is much higher for JNJ-10287069, especially in rats and monkeys. Therefore, it is anticipated that JNJ-10287069 should reach efficacious blood levels more rapidly than JNJ-10280205, thus, a faster onset of action. From the preclinical data presented above, it seems that JNJ-10287069 would be a better candidate for clinical study.
However, when taken into human, JNJ-10280205 showed excellent bioavailability, albeit in a different vehicle than the one used in animal studies, and desirable half-life (data not published). When dosed in a similar vehicle as used in animal studies, JNJ-10287069 also showed good exposure, although with lower C max than JNJ-10280205 when given the same dose.
Both compounds were mainly metabolized by CYP3A4 in vitro. In addition, JNJ-10280205 was moderately metabolized by CYP1A2 and JNJ-10287069 by CYP2D6. So inhibitors of these enzymes may decrease the metabolism of the JNJ compounds. The JNJ compounds inhibit CYP enzymes at much higher concentrations than those inhibiting PDE5. It is unlikely that they would affect the metabolism of other drugs at therapeutic doses. Inhibition of the HERG channel may result in QT prolongation and cardiac arrhythmia. Thus, it is important to determine the effect of our compounds on this channel. The IC 50 on HERG channel inhibition was 174 000 and 24 000 times higher than the K i on PDE5 for JNJ-10280205 and JNJ-10287069, respectively. Therefore, cross inhibition at therapeutic dose is not expected.
Currently, there are three PDE5 inhibitors in the market. Vardenafil is very similar to sildenafil, both in terms of its PDE selectivity profile and its pharmacokinetic properties. The T 1/2 for these two compounds is about 4 h, which means the patient needs to plan when taking these two drugs. 9, 29 Tadalafil, with an improved selectivity profile, has a T 1/2 of 17.5 h. 30 Although the long half-life means a longer duration of action and more spontaneity, the presence of a PDE5 inhibitor in the body for a prolonged period of time may not be desirable. Therefore, a PDE5 inhibitor with better selectivity profile than sildenafil and an intermediate half-life could be an attractive alternative for erectile dysfunction patients.
In summary, we have identified two novel and very potent PDE5 inhibitors, JNJ-10280205 and JNJ-10287069. Their overall selectivity against other PDEs tested was excellent. Both compounds were as efficacious as sildenafil in an anesthetized dog erectile model. Although JNJ-10287069 had better bioavailability in animal studies, both compounds showed good exposure in humans (unpublished). JNJ-10280205 and JNJ-10287069 are good research tools for studying PDE5 functions and have great clinical potential.
